Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1620846

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1620846

Retinitis Pigmentosa Market by Type (Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, X-linked Retinitis Pigmentosa), Offering (Diagnosis, Treatment), End-use - Global Forecast 2025-2030

PUBLISHED:
PAGES: 183 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Retinitis Pigmentosa Market was valued at USD 9.85 billion in 2023, expected to reach USD 10.66 billion in 2024, and is projected to grow at a CAGR of 9.02%, to USD 18.04 billion by 2030.

Retinitis Pigmentosa (RP) is a group of rare genetic disorders characterized by the breakdown and loss of cells in the retina, which often leads to vision impairment and blindness. The market scope encompasses therapeutics, assistive technologies, and genetic testing and counseling services aimed at managing and diagnosing the condition. The necessity of advancements in this field stems from the demand for effective treatments, as current therapies are primarily palliative. The application scope spans from pharmacological interventions such as gene therapies and retinal implants to technologically advanced visual aids. The end-use scope includes hospitals, eye care clinics, and research institutions that are actively involved in deploying and developing these solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 9.85 billion
Estimated Year [2024] USD 10.66 billion
Forecast Year [2030] USD 18.04 billion
CAGR (%) 9.02%

Key growth factors influencing the RP market include increasing prevalence rates due to better diagnostic capabilities, advancements in biotechnology, and rising investment in genetic research. The development of innovative treatments like CRISPR-based gene editing and novel drug delivery systems offers significant potential opportunities. Companies should focus on strategic partnerships and collaborations to accelerate research and expand their product pipelines. However, market growth faces challenges such as high treatment costs, limited awareness, and stringent regulatory hurdles, especially concerning gene therapies.

Innovative areas poised for research and development include gene therapy, stem cell therapy, and development of wearable visual aids. Engaging in these areas may lead to breakthroughs that significantly impact the market landscape. Such endeavors are likely to find traction not only in developing better therapeutic solutions but also in enhancing assistive technologies that improve the quality of life for patients.

While the RP market is highly specialized and somewhat fragmented, focused investment in R&D and technology can provide significant room for growth. Crafting policies that bolster patient access, coupled with educational campaigns to increase awareness, can mitigate existing limitations, further expanding market opportunities and contributing towards sustainable business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Retinitis Pigmentosa Market

The Retinitis Pigmentosa Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of rare eye diseases affecting retina worldwide
    • Growing emphasis on genetic therapies and personalized medicine
  • Market Restraints
    • Accessibility and affordability of treatments required for retinitis pigmentosa
  • Market Opportunities
    • Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
    • Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
  • Market Challenges
    • Lack of awareness and misdiagnosis of the condition

Porter's Five Forces: A Strategic Tool for Navigating the Retinitis Pigmentosa Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Retinitis Pigmentosa Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Retinitis Pigmentosa Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Retinitis Pigmentosa Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Retinitis Pigmentosa Market

A detailed market share analysis in the Retinitis Pigmentosa Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Retinitis Pigmentosa Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Retinitis Pigmentosa Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Retinitis Pigmentosa Market

A strategic analysis of the Retinitis Pigmentosa Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Retinitis Pigmentosa Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Astellas Pharma Inc., Beacon Therapeutics Limited, BIOGEN INC., Clino Corporation, Coave Therapeutics SA, Editas Medicine, Inc., GENSIGHT BIOLOGICS, Genethon, Johnson & Johnson Services, Inc., MeiraGTx Holdings PLC, Mimetogen Pharmaceuticals, Nacuity Pharmaceuticals, Inc., Novartis AG, Orphagen Pharmaceuticals, Inc., Oxford Biomedica PLC, Precision BioSciences, Inc., ProQR Therapeutics N.V., Sanofi S.A., Santen Pharmaceutical Co., Ltd., Spark Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., and The Wyanoke Group.

Market Segmentation & Coverage

This research report categorizes the Retinitis Pigmentosa Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, and X-linked Retinitis Pigmentosa.
  • Based on Offering, market is studied across Diagnosis and Treatment.
  • Based on End-use, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-7A1CEDCFE674

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of rare eye diseases affecting retina worldwide
      • 5.1.1.2. Growing emphasis on genetic therapies and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Accessibility and affordability of treatments required for retinitis pigmentosa
    • 5.1.3. Opportunities
      • 5.1.3.1. Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
      • 5.1.3.2. Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness and misdiagnosis of the condition
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Burgeoning cases of retinitis pigmentosa due to autosomal dominant retinitis pigmentosa
    • 5.2.2. End-use: Evolving utilization of specialty clinics for the treatment and management of retinitis pigmentosa
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Retinitis Pigmentosa Market, by Type

  • 6.1. Introduction
  • 6.2. Autosomal Dominant Retinitis Pigmentosa
  • 6.3. Autosomal Recessive Retinitis Pigmentosa
  • 6.4. X-linked Retinitis Pigmentosa

7. Retinitis Pigmentosa Market, by Offering

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Treatment

8. Retinitis Pigmentosa Market, by End-use

  • 8.1. Introduction
  • 8.2. Homecare
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Retinitis Pigmentosa Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Retinitis Pigmentosa Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Retinitis Pigmentosa Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. jCyte's jCell Therapy Enters Phase 3 Trials for Retinitis Pigmentosa
    • 12.3.2. Janssen Acquires Rights to Pioneering XLRP Gene Therapy from MeiraGTx, Catalyzing Advancements in Retinal Diseases
    • 12.3.3. The RD Fund Backs NVasc's Breakthrough in Retinal Therapeutics
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4D Molecular Therapeutics, Inc.
  • 2. Astellas Pharma Inc.
  • 3. Beacon Therapeutics Limited
  • 4. BIOGEN INC.
  • 5. Clino Corporation
  • 6. Coave Therapeutics SA
  • 7. Editas Medicine, Inc.
  • 8. GENSIGHT BIOLOGICS
  • 9. Genethon
  • 10. Johnson & Johnson Services, Inc.
  • 11. MeiraGTx Holdings PLC
  • 12. Mimetogen Pharmaceuticals
  • 13. Nacuity Pharmaceuticals, Inc.
  • 14. Novartis AG
  • 15. Orphagen Pharmaceuticals, Inc.
  • 16. Oxford Biomedica PLC
  • 17. Precision BioSciences, Inc.
  • 18. ProQR Therapeutics N.V.
  • 19. Sanofi S.A.
  • 20. Santen Pharmaceutical Co., Ltd.
  • 21. Spark Therapeutics, Inc.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. The Wyanoke Group
Product Code: MRR-7A1CEDCFE674

LIST OF FIGURES

  • FIGURE 1. RETINITIS PIGMENTOSA MARKET RESEARCH PROCESS
  • FIGURE 2. RETINITIS PIGMENTOSA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RETINITIS PIGMENTOSA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RETINITIS PIGMENTOSA MARKET DYNAMICS
  • TABLE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!